Country: United States
Language: English
Source: NLM (National Library of Medicine)
Ezetimibe (UNII: EOR26LQQ24) (Ezetimibe - UNII:EOR26LQQ24)
Prasco Laboratories
Ezetimibe
Ezetimibe 10 mg
PRESCRIPTION DRUG
New Drug Application Authorized Generic
EZETIMIBE- EZETIMIBE TABLET PRASCO LABORATORIES ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE EZETIMIBE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR EZETIMIBE TABLETS. EZETIMIBE TABLETS INITIAL U.S. APPROVAL: 2002 INDICATIONS AND USAGE Ezetimibe is an inhibitor of intestinal cholesterol (and related phytosterol) absorption indicated as an adjunct to diet to: Reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with primary hyperlipidemia, alone or in combination with an HMG-CoA reductase inhibitor (statin) (1.1) Reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with mixed hyperlipidemia in combination with fenofibrate (1.1) Reduce elevated total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH), in combination with atorvastatin or simvastatin (1.2) Reduce elevated sitosterol and campesterol in patients with homozygous sitosterolemia (phytosterolemia) (1.3) Limitations of Use (1.4) The effect of ezetimibe on cardiovascular morbidity and mortality has not been determined. Ezetimibe has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. DOSAGE AND ADMINISTRATION One 10-mg tablet once daily, with or without food (2.1) Dosing of ezetimibe should occur either ≥2 hours before or ≥4 hours after administration of a bile acid sequestrant. (2.3, 7.4) DOSAGE FORMS AND STRENGTHS Tablets: 10 mg (3) CONTRAINDICATIONS Statin contraindications apply when ezetimibe is used with a statin: Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels (4, 5.2) Women who are pregnant or may become pregnant (4, 8.1) Nursing mothers (4, 8.3) Known hypersensitivity to product components (4, 6.2) WARNINGS AND PRECAUTIONS Ezetimibe is not recommended in patients with moderate or severe hepatic impairment. (5.4, 8.7, 12.3) Liver enzyme abnormalities and monitoring: Persistent elevations in hepatic transaminase can occur when ezetim Read the complete document